IllnessThrombozytopenien + Thrombozytopathien, hereditäre; Differentialdiagnose
Summary
Comprehensive differential diagnostic panel for Thrombocytopenias + thrombocytopathies comprising 25 or altogether 59 curated genes according to the clinical signs
Loci type | Count |
---|---|
Gen | 55 |
127,9 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Loci panel
Gen
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
GP1BA | 1959 | NM_000173.7 | AD, AR | |
GP1BB | 621 | NM_000407.5 | AD, AR | |
GP9 | 534 | NM_000174.5 | AR | |
ITGA2B | 3120 | NM_000419.5 | AD, AR | |
ITGB3 | 2367 | NM_000212.3 | AD, AR | |
NBEAL2 | 8265 | NM_015175.3 | AR | |
ABCG5 | 1956 | NM_022436.3 | AR | |
ABCG8 | 2022 | NM_022437.3 | AR | |
ACTB | 1128 | NM_001101.5 | AD | |
ACTN1 | 2745 | NM_001130004.2 | AD | |
ACVRL1 | 1512 | NM_000020.3 | AD | |
ANKRD26 | 5133 | NM_014915.3 | AD | |
ANO6 | 2733 | NM_001025356.3 | AR | |
AP3B1 | 3138 | NM_001271769.2 | AR | |
ARPC1B | 1141 | NM_005720.4 | AR | |
BLOC1S3 | 609 | NM_212550.5 | AR | |
BLOC1S6 | 519 | NM_012388.4 | AR | |
CDC42 | 576 | NM_001791.4 | AD | |
CYCS | 318 | NM_018947.6 | AD | |
DIAPH1 | 3819 | NM_005219.5 | AD | |
DTNBP1 | 813 | NM_001271667.2 | AR | |
ETV6 | 1359 | NM_001987.5 | AD | |
FERMT3 | 1992 | NM_031471.6 | AR | |
FLI1 | 1359 | NM_002017.5 | AD, AR | |
FLNA | 7920 | NM_001456.4 | XL | |
FYB1 | 2783 | NM_001243093.2 | AR | |
GATA1 | 1242 | NM_002049.4 | XLR | |
GFI1B | 993 | NM_004188.8 | AD, AR | |
GNE | 2262 | NM_001128227.3 | AR | |
GP6 | 1863 | NM_001083899.2 | AR | |
HOXA11 | 942 | NM_005523.6 | AD | |
HPS1 | 2103 | NM_000195.5 | AR | |
HPS3 | 3015 | NM_032383.5 | AR | |
HPS4 | 2127 | NM_022081.6 | AR | |
HPS5 | 3048 | NM_007216.4 | AR | |
HPS6 | 2328 | NM_024747.6 | AR | |
MECOM | 3351 | NM_001105077.4 | AD | |
MPIG6B | 910 | NM_025260.4 | AR | |
MPL | 1908 | NM_005373.3 | AR, AD | |
MYH9 | 5883 | NM_002473.6 | AD | |
PLA2G4A | 2250 | NM_024420.3 | AR | |
PLAU | 1245 | NM_001145031.3 | AD | |
PRKACG | 1056 | NM_002732.4 | AR | |
PTPN11 | 1782 | NM_002834.5 | AD | |
RASGRP2 | 1830 | NM_153819.1 | AR | |
RUNX1 | 1443 | NM_001754.5 | AD | |
SLFN14 | 2743 | NM_001129820.2 | AD | |
SRC | 1611 | NM_005417.5 | AD | |
STIM1 | 2058 | NM_003156.4 | AD | |
TBXA2R | 1032 | NM_001060.6 | AD, AR | |
THBD | 1728 | NM_000361.3 | AD | |
THPO | 1062 | NM_000460.4 | AD | |
TNXB | 12729 | NM_019105.8 | AR | |
TUBB1 | 1356 | NM_030773.4 | AD, AR | |
WAS | 1509 | NM_000377.3 | XLR |
Informations about the disease
Group of diseases
- Allelic: Alzheimer disease, late-onset, susceptibility to (PLAU)
- Allelic: Amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to (TRPM7)
- Allelic: Anemia, XL, with/without neutropenia and/or platelet abnormalities (GATA1)
- Allelic: Cardiac valvular dysplasia, XL (FLNA)
- Allelic: Colon cancer, advanced, somatic (SRC)
- Allelic: Deafness, AD 17 (MYH9)
- Allelic: Erythrokeratodermia variabilis et progressiva 4 (KDSR)
- Allelic: FG syndrome 2 (FLNA)
- Allelic: Frontometaphyseal dysplasia 1 (FLNA)
- Allelic: Hemolytic uremic syndrome, atypical, susceptibility to, 6 (THBD)
- Allelic: Heterotopia, periventricular, 1 (FLNA)
- Allelic: Leukemia, acute myeloid (RUNX1)
- Allelic: Leukemia, acute myeloid, somatic (ETV6)
- Allelic: Leukemia, megakaryoblastic, with/-out Down syndrome, somatic (GATA1)
- Allelic: Melnick-Needles syndrome (FLNA)
- Allelic: Metachondromatosis (PTPN11)
- Allelic: Myelofibrosis with myeloid metaplasia, somatic (MPL)
- Allelic: Myocardial infarction, susceptibility to (ITGB3)
- Allelic: Neutropenia, severe congenital, XL (WASP)
- Allelic: Nonarteritic anterior ischemic optic neuropathy, susceptibility to (GP1BA)
- Allelic: Otopalatodigital syndrome, type I (FLNA)
- Allelic: Otopalatodigital syndrome, type II (FLNA)
- Allelic: Purpura, posttransfusion (ITGB3)
- Allelic: Seizures, cortical blindness, microcephaly syndrome (DIAPH1)
- Allelic: Terminal osseous dysplasia (FLNA)
- Allelic: Thrombocytopenia, neonatal alloimmune (ITGB3)
- Allelic: Thrombocytopenia, neonatal alloimmune, BAK antigen related (ITGA2B)
- Allelic: Vesicoureteral reflux 8 (TNXB)
- Allelic: Wiskott-Aldrich syndrome (WASP)
- Bernard-Soulier syndrome, type B (GP1BB)
- Bernard-Soulier syndrome, type C (GP9)
- Bernard-Soulier syndrome, types A1 [AR] + A2 [AD] (GP1BA)
- Bleeding disorder, platelet-type, 1 [Bernard-Soulier syndrome] (GP9, GP1BA, GP1BB)
- Bleeding disorder, platelet-type, 11 (GP6)
- Bleeding disorder, platelet-type, 12 (PTGS1)
- Bleeding disorder, platelet-type, 13, susceptibility to (TBXA2R)
- Bleeding disorder, platelet-type, 15 (ACTN1)
- Bleeding disorder, platelet-type, 16, AD (ITGA2B)
- Bleeding disorder, platelet-type, 17 (GFI1B)
- Bleeding disorder, platelet-type, 18 (RASGRP)
- Bleeding disorder, platelet-type, 19 (PRKACG)
- Bleeding disorder, platelet-type, 20 (SLFN14)
- Bleeding disorder, platelet-type, 21 (FLI1)
- Bleeding disorder, platelet-type, 24, AD (ITGB3)
- Bleeding disorder, platelet-type, 7 [Scott syndrome] (ANO6)
- Bleeding disorder, platelet-type, 8 (P2RY12)
- Congenital short bowel syndrome (FLNA)
- Deafness, AD 1, with/-out thrombocytopenia (DIAPH1)
- Dominant macrothrombocytopenia, mild bleeding, disrupted cytoskeleton remodeling [lit.] (TPM4)
- Ehlers-Danlos syndrome due to tenascin X deficiency [panelapp] (TNXB)
- Ehlers-Danlos syndrome, classic-like, 1 (TNXB)
- Ehlers-Danlos syndrome, musculocontractural type 1 (CHST14)
- Gastrointestinal ulceration, recurrent, with dysfunctional platelets (PLA2G4A)
- Ghosal hematodiaphyseal syndrome (TBXAS1)
- Giant platelet disorder, isolated (GP1BB)
- Glanzmann thrombasthenia (ITGA2B, ITGB3)
- Gray platelet syndrome (NBEAL2)
- Hemophagocytic lymphohistiocytosis, familial, 3 (UNC13D)
- Hemophagocytic lymphohistiocytosis, familial, 5, with/-out microvillus inclusion disease (STXBP2)
- Hermansky-Pudlak syndrome 1, 3, 4, 5, 6 (HPS1, HPS3, HPS4, HPS5, HPS6)
- Hermansky-Pudlak syndrome 10 (AP3D1)
- Hermansky-Pudlak syndrome 2 (AP3B1)
- Hermansky-Pudlak syndrome 7 (DTNBP1)
- Hermansky-Pudlak syndrome 8, 9 (BLOC1S3, BLOC1S6)
- Immunodeficiency 71 with inflammatory disease + congenital thrombocytopenia (ARPC1B)
- Inherited Thrombocytopenia assiciated with mutation of UDP-Galactose-4-Epimerase (GALE)
- Intestinal pseudoobstruction, neuronal (FLNA)
- LEOPARD syndrome 1 (PTPN11)
- Leukocyte adhesion deficiency, type III (FERMT3)
- Macrothrombocytopenia + granulocyte incl. with/-out nephritis/sensorineural hearing loss (MYH9)
- Macrothrombocytopenia [panelapp] (TRPM7)
- Macrothrombocytopenia, AD, TUBB1-related (TUBB1)
- Myopathy associated with thrombocytopenia [panelapp] (GNE)
- Noonan syndrome 1 (PTPN11)
- Platelet disorder, familial, with associated myeloid malignancy (RUNX1)
- Purinergic receptor P2X, ligand-gated ion channel, 1 deficiency (P2RX1)
- Quebec platelet disorder (PLAU)
- Radioulnar synostosis with amegakaryocytic thrombocytopenia 1 (HOXA11)
- Radioulnar synostosis with amegakaryocytic thrombocytopenia 2 (MECOM)
- Recessive severe thrombocytopenia with progression to marrow fibrosis at young age [panelapp] (KDSR)
- Significant bruising/haematomas [panelapp] (TNXB)
- Sitosterolemia 1 (ABCG8)
- Sitosterolemia 2 (ABCG5)
- Stormorken syndrome [YORK platelet syndrome] (STIM1)
- Takenouchi-Kosaki syndrome (CDC42)
- Telangiectasia, hereditary hemorrhagic, type 1 (ENG)
- Telangiectasia, hereditary hemorrhagic, type 2 (ACVRL1)
- Thrombocythemia 1 (THPO)
- Thrombocythemia 2 (MPL)
- Thrombocytopenia 2 (ANKRD26)
- Thrombocytopenia 3 (FYB1)
- Thrombocytopenia 4 (CYCS)
- Thrombocytopenia 5 (ETV6)
- Thrombocytopenia 6 (SRC)
- Thrombocytopenia with beta-thalassemia, XL (GATA1)
- Thrombocytopenia, AD, 7 (IKZF5)
- Thrombocytopenia, XL (WASP)
- Thrombocytopenia, XL, intermittent (WASP)
- Thrombocytopenia, XL, with/-out dyserythropoietic anemia (GATA1)
- Thrombocytopenia, anemia + myelofibrosis (MPIG6B)
- Thrombocytopenia, congenital amegakaryocytic (MPL)
- Thrombocytopenia, neonatal alloimmune (ITGB3)
- Thrombocytopenia-absent radius syndrome (RBM8A)
- Thrombophilia due to thrombomodulin defect (THBD)
- Thrombotic thrombocytopenic purpura, hereditary (ADAMTS13)
- von Willebrand disease, platelet-type (GP1BA)
- von Willebrand disease, type 1 (VWF)
- von Willebrand disease, type 3 (VWF)
- von Willebrand disease, types 2A, 2B, 2M + 2N (VWF)
- AD
- AR
- XL
- XLR
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.